Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald Radich

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
The New England Journal of Medicine|March 25, 2026
Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income CountriesAlicia Annamalay, Inés García González, Colin Forsyth, et al.
Nature Genetics|June 2, 2009
Lin28 promotes transformation and is associated with advanced human malignanciesSrinivas R Viswanathan, John T Powers, William Einhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Mayo Clinic Proceedings|July 28, 2015
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsAyalew Tefferi, Hagop Kantarjian, S Vincent Rajkumar, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
Leukemia & Lymphoma|December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Blood|August 16, 2003
Allogeneic hematopoietic stem cell transplantation for myelofibrosisH Joachim Deeg, Theodore A Gooley, Mary E D Flowers, et al.
The New England Journal of Medicine|March 25, 2026
Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income CountriesAlicia Annamalay, Inés García González, Colin Forsyth, et al.
Nature Genetics|June 2, 2009
Lin28 promotes transformation and is associated with advanced human malignanciesSrinivas R Viswanathan, John T Powers, William Einhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2023
CML and the WHO: Why?Ellin Berman, Neil P Shah, Michael Deninger, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Mayo Clinic Proceedings|July 28, 2015
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsAyalew Tefferi, Hagop Kantarjian, S Vincent Rajkumar, et al.
Pageof 10